AI Tokens
Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Analysis of Profitability Ratios

Microsoft Excel

Profitability Ratios (Summary)

Return on Sales

Return on Investment

IQVIA Holdings Inc., profitability ratios

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Return on Sales
Gross profit margin 34.89% 33.45% 33.97% 34.16% 35.21%
Operating profit margin 12.48% 10.04% 6.44% 7.01% 7.12%
Net profit margin 7.57% 6.96% 2.46% 1.72% 2.49%
Return on Investment
Return on equity (ROE) 18.92% 15.99% 4.65% 3.18% 3.86%
Return on assets (ROA) 4.31% 3.91% 1.14% 0.82% 1.15%

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


A comprehensive review of profitability ratios from 2018 to 2022 reveals a distinct two-phase trajectory. The period between 2018 and 2020 was characterized by relative stagnation and slight volatility, followed by a sharp inflection point in 2021 that led to significant expansions in both operational efficiency and investment returns.

Profit Margin Trends
Gross profit margin remained relatively stable throughout the five-year period, fluctuating within a narrow range between 33.45% and 35.21%. Despite a slight downward trend through 2021, it recovered to 34.89% by the end of 2022. In contrast, operating profit margin showed substantial growth after 2020, rising from 6.44% to 12.48% by 2022. Net profit margin mirrored this positive shift, increasing from 2.46% in 2020 to 7.57% in 2022, indicating a marked improvement in the conversion of revenue to net income.
Efficiency and Return Metrics
Return on equity (ROE) experienced the most dramatic acceleration, climbing from 4.65% in 2020 to 18.92% in 2022. This surge suggests a significant increase in the effectiveness of equity utilization to generate profit. Similarly, return on assets (ROA) improved from 1.14% in 2020 to 4.31% in 2022, reflecting enhanced asset productivity and more efficient management of the balance sheet.
Overall Profitability Synthesis
The divergence between the stable gross margin and the rapidly increasing operating and net margins suggests that profitability gains were driven primarily by operational efficiencies and cost management rather than pricing power or changes in the cost of goods sold. The synchronized rise in ROE and ROA from 2021 onwards confirms a robust strengthening of the overall financial performance profile.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Gross Profit Margin

IQVIA Holdings Inc., gross profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Gross profit 5,028 4,641 3,859 3,788 3,666
Revenues 14,410 13,874 11,359 11,088 10,412
Profitability Ratio
Gross profit margin1 34.89% 33.45% 33.97% 34.16% 35.21%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc. 70.00% 68.96% — — —
Amgen Inc. 74.17% 73.44% — — —
Bristol-Myers Squibb Co. 78.04% 78.57% — — —
Danaher Corp. 60.21% 60.95% — — —
Eli Lilly & Co. 76.77% 74.18% — — —
Gilead Sciences Inc. 79.03% 75.56% — — —
Johnson & Johnson 67.26% 68.16% — — —
Merck & Co. Inc. 70.63% 72.02% — — —
Pfizer Inc. 66.05% 62.48% — — —
Regeneron Pharmaceuticals Inc. 87.18% 84.83% — — —
Thermo Fisher Scientific Inc. 42.24% 50.08% — — —
Vertex Pharmaceuticals Inc. 87.90% 88.06% — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenues
= 100 × 5,028 ÷ 14,410 = 34.89%

2 Click competitor name to see calculations.


The financial performance from 2018 to 2022 is characterized by consistent growth in both total revenues and absolute gross profit, accompanied by a period of margin compression followed by a recovery in the final year.

Revenue and Gross Profit Expansion
Revenues demonstrated a steady upward trajectory, increasing from 10,412 million US$ in 2018 to 14,410 million US$ by 2022. During the same period, gross profit rose from 3,666 million US$ to 5,028 million US$. A significant acceleration in growth is observed between 2020 and 2021, where gross profit increased by approximately 20.3% in a single fiscal year.
Gross Profit Margin Dynamics
The gross profit margin experienced a gradual decline between 2018 and 2021, falling from 35.21% to a minimum of 33.45%. This downward trend indicates that the cost of sales grew at a slightly faster pace than revenue growth during this four-year interval.
Margin Recovery
A reversal of the previous downward trend occurred in 2022, with the gross profit margin rising to 34.89%. This improvement suggests enhanced operational efficiency or a favorable shift in the mix of services and products sold, bringing the profitability ratio near its 2018 levels.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Operating Profit Margin

IQVIA Holdings Inc., operating profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Income from operations 1,799 1,393 731 777 741
Revenues 14,410 13,874 11,359 11,088 10,412
Profitability Ratio
Operating profit margin1 12.48% 10.04% 6.44% 7.01% 7.12%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 31.21% 31.89% — — —
Amgen Inc. 38.57% 31.44% — — —
Bristol-Myers Squibb Co. 17.96% 15.91% — — —
Danaher Corp. 27.61% 25.35% — — —
Eli Lilly & Co. 24.97% 22.45% — — —
Gilead Sciences Inc. 27.17% 36.72% — — —
Johnson & Johnson 24.63% 24.95% — — —
Merck & Co. Inc. 30.27% 25.74% — — —
Pfizer Inc. 35.37% 24.70% — — —
Regeneron Pharmaceuticals Inc. 38.93% 55.67% — — —
Thermo Fisher Scientific Inc. 18.69% 25.57% — — —
Vertex Pharmaceuticals Inc. 48.23% 36.73% — — —
Operating Profit Margin, Sector
Pharmaceuticals, Biotechnology & Life Sciences 28.59% 26.98% — — —
Operating Profit Margin, Industry
Health Care 18.74% 18.04% — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Operating profit margin = 100 × Income from operations ÷ Revenues
= 100 × 1,799 ÷ 14,410 = 12.48%

2 Click competitor name to see calculations.


Between 2018 and 2022, the operational performance exhibited a distinct two-phase trajectory characterized by initial margin compression followed by a period of significant expansion.

Revenue and Operating Income Growth
Revenues demonstrated consistent year-over-year growth, increasing from 10,412 million USD in 2018 to 14,410 million USD in 2022. However, the growth in income from operations was non-linear. Following a period of relative stagnation between 2018 and 2020, where income fluctuated between 731 million and 777 million USD, a substantial acceleration occurred in 2021 and 2022, with operating income reaching 1,799 million USD by the end of the period.
Operating Profit Margin Evolution
The operating profit margin experienced a gradual decline during the first three years, dropping from 7.12% in 2018 to a low of 6.44% in 2020. This trend indicates that operating expenses grew at a rate slightly exceeding revenue growth during this timeframe. Conversely, a sharp pivot is observed starting in 2021, as the margin expanded to 10.04% and further climbed to 12.48% in 2022.
Operational Efficiency Analysis
The disparity between the growth rates of revenue and operating income in the final two years suggests a marked improvement in operational efficiency. While revenues increased by approximately 4% between 2021 and 2022, income from operations grew by approximately 29% during the same interval. This indicates a successful scaling of operations where incremental revenue contributed disproportionately to operating profit, resulting in an overall margin increase of 5.36 percentage points from the 2020 trough to the 2022 peak.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Net Profit Margin

IQVIA Holdings Inc., net profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net income attributable to IQVIA Holdings Inc. 1,091 966 279 191 259
Revenues 14,410 13,874 11,359 11,088 10,412
Profitability Ratio
Net profit margin1 7.57% 6.96% 2.46% 1.72% 2.49%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 20.39% 20.54% — — —
Amgen Inc. 26.42% 24.25% — — —
Bristol-Myers Squibb Co. 13.71% 15.08% — — —
Danaher Corp. 22.91% 21.84% — — —
Eli Lilly & Co. 21.88% 19.71% — — —
Gilead Sciences Inc. 17.02% 23.05% — — —
Johnson & Johnson 18.90% 22.26% — — —
Merck & Co. Inc. 24.49% 26.79% — — —
Pfizer Inc. 31.01% 26.76% — — —
Regeneron Pharmaceuticals Inc. 35.64% 50.25% — — —
Thermo Fisher Scientific Inc. 15.47% 19.70% — — —
Vertex Pharmaceuticals Inc. 37.20% 30.92% — — —
Net Profit Margin, Sector
Pharmaceuticals, Biotechnology & Life Sciences 22.55% 23.38% — — —
Net Profit Margin, Industry
Health Care 14.65% 15.24% — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
Net profit margin = 100 × Net income attributable to IQVIA Holdings Inc. ÷ Revenues
= 100 × 1,091 ÷ 14,410 = 7.57%

2 Click competitor name to see calculations.


The profitability profile of the organization underwent a significant transformation between 2018 and 2022, evolving from a period of marginal and volatile returns to a phase of substantial margin expansion. This shift is characterized by a sharp inflection point occurring after 2020, where profit growth decoupled from revenue growth to improve overall efficiency.

Revenue and Net Income Correlation
Revenues demonstrated a consistent upward trajectory, increasing from US$ 10,412 million in 2018 to US$ 14,410 million in 2022. While net income initially fluctuated—dropping to US$ 191 million in 2019 before recovering to US$ 279 million in 2020—it experienced exponential growth in the final two years of the period, reaching US$ 1,091 million by December 31, 2022.
Net Profit Margin Trends
The net profit margin remained compressed and relatively stable from 2018 to 2020, fluctuating between a high of 2.49% and a low of 1.72%. A dramatic escalation is observed starting in 2021, with the margin rising to 6.96%, and further expanding to 7.57% in 2022. This represents a more than three-fold increase in the percentage of revenue retained as net income compared to the 2020 baseline.
Operational Efficiency Insights
The data indicates a significant improvement in operational leverage. Between 2020 and 2022, net income grew at a rate far exceeding the growth of revenues. This pattern suggests that the organization successfully optimized its cost structure or shifted toward higher-margin revenue streams, resulting in a strengthened bottom line relative to top-line expansion.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Return on Equity (ROE)

IQVIA Holdings Inc., ROE calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net income attributable to IQVIA Holdings Inc. 1,091 966 279 191 259
Equity attributable to IQVIA Holdings Inc.’s stockholders 5,765 6,042 6,001 6,003 6,714
Profitability Ratio
ROE1 18.92% 15.99% 4.65% 3.18% 3.86%
Benchmarks
ROE, Competitors2
AbbVie Inc. 68.60% 74.91% — — —
Amgen Inc. 178.97% 87.96% — — —
Bristol-Myers Squibb Co. 20.37% 19.46% — — —
Danaher Corp. 14.39% 14.24% — — —
Eli Lilly & Co. 58.64% 62.16% — — —
Gilead Sciences Inc. 21.62% 29.55% — — —
Johnson & Johnson 23.36% 28.20% — — —
Merck & Co. Inc. 31.57% 34.17% — — —
Pfizer Inc. 32.79% 28.47% — — —
Regeneron Pharmaceuticals Inc. 19.14% 43.03% — — —
Thermo Fisher Scientific Inc. 15.80% 18.94% — — —
Vertex Pharmaceuticals Inc. 23.88% 23.19% — — —
ROE, Sector
Pharmaceuticals, Biotechnology & Life Sciences 27.99% 29.75% — — —
ROE, Industry
Health Care 24.82% 25.44% — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
ROE = 100 × Net income attributable to IQVIA Holdings Inc. ÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 100 × 1,091 ÷ 5,765 = 18.92%

2 Click competitor name to see calculations.


The Return on Equity (ROE) experienced a significant transformation between 2018 and 2022, transitioning from a period of relative stagnation to a phase of rapid growth.

Net Income Trajectory
Between 2018 and 2020, net income attributable to stockholders remained volatile and relatively low, fluctuating between US$ 191 million and US$ 279 million. A substantial increase in profitability began in 2021, with net income rising to US$ 966 million and further increasing to US$ 1,091 million by the end of 2022.
Equity Base Trends
Equity attributable to stockholders exhibited a gradual decline over the five-year period. The balance decreased from US$ 6,714 million in 2018 to US$ 5,765 million in 2022. This consistent reduction in the equity base occurred simultaneously with the scaling of net income, which mathematically contributed to an amplified ROE.
Return on Equity Analysis
ROE remained in the low single digits from 2018 through 2020, reaching a minimum of 3.18% in 2019. A sharp inflection point occurred in 2021, where the ratio surged to 15.99%, subsequently climbing to 18.92% in 2022. The expansion of the ROE is predominantly driven by the exponential growth in net income, which far outweighed the modest contraction in stockholders' equity.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Return on Assets (ROA)

IQVIA Holdings Inc., ROA calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Net income attributable to IQVIA Holdings Inc. 1,091 966 279 191 259
Total assets 25,337 24,689 24,564 23,251 22,549
Profitability Ratio
ROA1 4.31% 3.91% 1.14% 0.82% 1.15%
Benchmarks
ROA, Competitors2
AbbVie Inc. 8.53% 7.88% — — —
Amgen Inc. 10.06% 9.63% — — —
Bristol-Myers Squibb Co. 6.53% 6.40% — — —
Danaher Corp. 8.55% 7.73% — — —
Eli Lilly & Co. 12.62% 11.44% — — —
Gilead Sciences Inc. 7.27% 9.16% — — —
Johnson & Johnson 9.57% 11.47% — — —
Merck & Co. Inc. 13.30% 12.35% — — —
Pfizer Inc. 15.91% 12.11% — — —
Regeneron Pharmaceuticals Inc. 14.85% 31.75% — — —
Thermo Fisher Scientific Inc. 7.15% 8.12% — — —
Vertex Pharmaceuticals Inc. 18.30% 17.44% — — —
ROA, Sector
Pharmaceuticals, Biotechnology & Life Sciences 10.67% 10.42% — — —
ROA, Industry
Health Care 9.66% 9.46% — — —

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 2022 Calculation
ROA = 100 × Net income attributable to IQVIA Holdings Inc. ÷ Total assets
= 100 × 1,091 ÷ 25,337 = 4.31%

2 Click competitor name to see calculations.


The financial performance between 2018 and 2022 is characterized by a marked acceleration in profitability relative to a steady expansion of the asset base. While the initial period showed volatility in earnings, the subsequent years demonstrate a significant increase in the efficiency of asset utilization.

Net Income Trends
Net income exhibited a fluctuating trend early in the period, declining from US$ 259 million in 2018 to US$ 191 million in 2019. However, a strong recovery began in 2020, followed by a substantial surge to US$ 966 million in 2021 and reaching US$ 1,091 million by 2022. This trajectory indicates a significant escalation in bottom-line profitability toward the end of the analyzed period.
Total Asset Growth
Total assets grew at a consistent and moderate pace, increasing from US$ 22,549 million in 2018 to US$ 25,337 million in 2022. The expansion of the asset base remained linear, suggesting a stable growth in the company's structural scale without abrupt capital expenditures or divestments.
Return on Assets (ROA) Dynamics
The ROA closely mirrored the volatility and subsequent growth of net income. After a decrease to 0.82% in 2019, the ratio recovered to 1.14% in 2020. A pivotal increase occurred in 2021, where the ROA rose to 3.91%, further improving to 4.31% in 2022. This trend demonstrates that the growth in net income significantly outpaced the growth of total assets, resulting in a substantial improvement in the company's ability to generate earnings from its invested capital.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?